Regulus Therapeutics
在场
Regulus Therapeutics 是一家在股票代码 RGLS (US) 下上市的公司。
高管
查看带有其 23 名主要高管的组织结构图
Regulus Therapeutics 搜索最多的简介
- Joseph Hagan, President, Chief Executive Officer and Director
- David Baltimore, Director
- Kathryn Collier, Director
高管在Regulus Therapeutics变化
- Rekha Garg 曾任 Senior Vice President, Clinical Development and Regulatory, 现升职为 Chief Medical Officer (新闻发布的2024五月17号).
创建提醒
跟踪 Regulus Therapeutics 的高管变动
生物技术
Regulus Therapeutics 拥有 2,327 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Chromocell的新名称是Channel Therapeutics Corporation。 (公布2024十一月22号).
- Enveda Biosciences 刚刚宣布为 130 筹款数百万美元。 (公布2024十一月22号).
- Alentis Therapeutics 刚刚宣布为 181 筹款数百万美元。 (公布2024十一月20号).
生物技术 行业的其他推荐联系人
消息
Regulus Therapeutics 的最新新闻稿
- Press Releases - Regulus Therapeutics
- Press Releases - Regulus Therapeutics
- Press Releases - Regulus Therapeutics
- Press Releases - Regulus Therapeutics
- Press Releases - Regulus Therapeutics
- Regulus Therapeutics to Present at the H.C. Wainwright Global Investment Conference | Regulus Therapeutics Inc.
- Regulus Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates | Regulus Therapeutics Inc.
- Regulus Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Regulus Therapeutics Inc.
- Regulus Therapeutics Announces Timing for First Quarter 2022 Financial Results Webcast and Conference Call | Regulus Therapeutics Inc.
- Regulus Therapeutics Announces Initiation of Preclinical Studies in Amyotrophic Lateral Sclerosis under a Collaboration Agreement with Harvard's Brigham and Women's Hospital | Regulus Therapeutics Inc.
- View more press releases Close
通过电子邮件
